

Protein assay

New ProcartaPlex Human Kidney Toxicity panels

Analyze up to 11 toxicity targets at the same time

Toxicity is crucial in biological research and plays an important role in drug development. Toxicity studies aim to remove toxic compounds early in the drug development process, as drug-induced toxicities are the leading cause of drug failures.

Organ-specific toxicity tests are of high interest, specifically those for the kidney. Kidneys are the body's central detoxification organs, and are exposed to drugs, reactive metabolites, and environmental chemicals. Kidney toxicity is routinely assessed during preclinical safety evaluations.

Nephrotoxicity research meets Invitrogen™ ProcartaPlex™ multiplex panels for the Luminex® platform

New Invitrogen™ ProcartaPlex™ Human Kidney Toxicity panels enable the simultaneous quantification of up to 11 targets in a single well. These immunoassays are available as single targets, preconfigured panels of targets, and custom-blended mix-and-match panels.

ProcartaPlex Human Kidney Toxicity assays have been tested in several sample types, including urine, serum, plasma, and cell culture supernatant.




Figure 1. Significantly increased protein markers in samples from individuals with acute kidney injury (AKI) or renal kidney failure (RKF) vs. controls. Thirty-seven urine samples were tested, including 14 controls, 10 acute kidney injury, and 13 renal kidney failure samples.




Figure 2. Forty urine samples of subjects with chronic kidney disease of uncertain etiology (CKDu) and 12 controls were tested with ProcartaPlex Human Kidney Toxicity panels. The concentration of 10 markers was significantly increased compared with samples of healthy donors.

Statistical significance

* P ≤ 0.05

** P ≤ 0.01

*** P ≤ 0.001

**** P ≤ 0.0001

Learn more at thermofisher.com/toxicologyimmunoassays

invitrogen